Literature DB >> 18083308

Evaluation of an enzyme-linked immunosorbent assay for the serological diagnosis of Neospora caninum infection in sheep and determination of the apparent prevalence of infection in New Zealand.

M P Reichel1, G P Ross, M M McAllister.   

Abstract

Neospora caninum has recently been shown to be a cause of abortions of sheep in New Zealand. A commercially available enzyme-linked immunosorbent assay (ELISA) was validated for use in sheep with sera from experimentally infected sheep. A cut-off threshold was established that demonstrated sero-conversion between 7 and 14 days post-infection. Higher inocula led to earlier sero-conversion. This ELISA was applied to 640 sera collected from rams across New Zealand and 0.625% (+/-0.61%) (4/640) were shown to be serologically positive. The four positive sera were also demonstrated to be positive by indirect fluorescent antibody test (IFAT). The ELISA evaluated here lends itself more readily to large-scale investigations than IFAT. The low background of N. caninum infection in the New Zealand sheep population suggests that N. caninum abortions could be more easily diagnosed by serological means than in populations with higher background sero-prevalence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18083308     DOI: 10.1016/j.vetpar.2007.11.002

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  2 in total

1.  Neospora caninum infection as a cause of reproductive failure in a sheep flock.

Authors:  Marta González-Warleta; José Antonio Castro-Hermida; Javier Regidor-Cerrillo; Julio Benavides; Gema Álvarez-García; Miguel Fuertes; Luis Miguel Ortega-Mora; Mercedes Mezo
Journal:  Vet Res       Date:  2014-08-26       Impact factor: 3.683

Review 2.  Ovine Neosporosis: The Current Global Situation.

Authors:  Julio Benavides; Marta González-Warleta; Noive Arteche-Villasol; Valentín Pérez; Mercedes Mezo; Daniel Gutiérrez-Expósito
Journal:  Animals (Basel)       Date:  2022-08-15       Impact factor: 3.231

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.